VEGF／VEGFR信号通路抑制剂疗效预测的研究进展

血管生成是肿瘤转移的基础，新生血管形成是肿瘤复发转移不可或缺的条件。血管内皮生长因子（VEGF）及其受体（VEGFR）是肿瘤血管形成过程中的重要调节因子。VEGF／VEGFR信号通路抑制剂已经成功进入临床应用阶段，但只有一部分患者能够从中获益。探索能够可靠预测VEGF／VEGFR信号通路抑制剂疗效的评价指标，将会给肿瘤患者带来更大的临床获益。本文将对VEGF/VEGFR信号通路抑制剂疗效预测指标的研究进展作一综述。

Progress of effectiveness prediction on VEGF/VEGFR signal pathway inhibitor

Angiogenesis is the basis of tumor metastasis, while neovasularization is the indispensable condition for tumor re- currence and metastasis. Vascular endothelial growth factor（VEGF） and its receptor（VEGFR） are important regulatory factors in for- mation of tumor blood vessels. The VEGF/VEGFR signal pathway inhibitors have been successfully applied to clinical, but only some patients can benefit from them. If we can explore reliable predictive indicators for response to VEGF/VEGFR signal pathway inhibitors, it will give patients much more clinical benefits. In this paper, we review the progress in predictive markers for response to VEGF/ VEGFR signal pathway inhibitors.